TAG:
pathology test
Price Cuts, Long Delays in Payment Are Expected
By Joseph Burns | From the Volume XIX No. 18 – December 31, 2012 Issue
CEO SUMMARY: In addition to a steep cut in the 88305 CPT code, anatomic pathology laboratories can expect cuts in the payment from Medicare for molecular and prostate biopsy testing. Two national experts in lab billing and reimbursement warn labs to expect confusion in how both public and…
Ascend Clinical Acquires PathCentral Lab Business
By Joseph Burns | From the Volume XIX No. 18 – December 31, 2012 Issue
CEO SUMMARY: Ascend Clinical and PathCentral see an opportunity to provide sophisticated services to community pathology groups. Ascend Clinical will expand the molecular diagnostic and gene sequencing business it is purchasing from PathCentral. PathCentral will concentrate on marketing i…
Of 88305-TC and Other Bad News for Pathology Labs
By R. Lewis Dark | From the Volume XIX No. 16 – November 19, 2012 Issue
BY NOW, VIRTUALLY ALL PATHOLOGISTS ARE AWARE of the announced cut in Medicare reimbursement for the technical component (TC) of CPT 88305. Effective on January 1, 2012, Medicare will pay 52% less for this CPT code. From the prior level of $69.78, the new reimbursement will be $33.70. As news of this…
Pathologists in China, U.S. Linked By Digital Pathology
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO Summary: It is one of the first clinical collaborations of this type to be anchored by use of digital pathology. Pathologists at the medical schools of the Second Affiliated Hospital of Zhejiang University in Hangzhou, China, and the University of California Los Angeles (UCLA) are exc…
Lab Restructuring Moves Ahead in United Kingdom and Ireland
By Robert Michel | From the Volume XIX No. 8 – June 4, 2012 Issue
IT IS TOUGH TIMES FINANCIALLY for pathology and clinical laboratories in the British Isles. In both the nations of the United Kingdom and Ireland, the budget woes of the respective national governments are driving major changes in the organization and delivery of laboratory testing services. In the …
Today’s Lab Test Model Won’t Survive Reforms
By Robert Michel | From the Volume XIX No. 4 – March 12, 2012 Issue
CEO SUMMARY: For more than three decades, independent lab companies have waxed fat by increasing their respective market share of lab test referrals from office-based physicians. This era is poised to end as growing numbers of office-based physicians begin to practice medicine within an a…
Shaw & Adelman Successful Support of Lab Networks Need Hospital Leadership
By Joseph Burns | From the Volume XIX No. 3 – February 20, 2012 Issue
CEO Summary: In the second installment of our exclusive two- part interview, the executive directors of two regional laboratory networks formed in the 1990s (one in Michigan and one in Washington State) share their assessment of why their respective lab networks have performed strongly ov…
2011’s Top 10 Lab Stories Point to a Busy 2012
By Robert Michel | From the Volume XIX No. 1 – January 9, 2012 Issue
CEO SUMMARY: Given the specific news stories that make up THE DARK REPORT’S list of the “Top Ten Lab Stories for 2011,” it might be said that 2011 was a rather quiet year overshadowed by anticipation of the coming reforms mandated by the Accountable Care Act of 2010. For the clinica…
Anatomic Path Insourcing Expected to Be Ongoing
By Robert Michel | From the Volume XVIII No. 16 – November 28, 2011 Issue
CEO SUMMARY: Insourcing of anatomic pathology services by office-based physicians has been especially prevalent and is increasing among three specialties (gastroenterology, urology, and dermatology), according to a survey conducted last month. Survey respondents also indicated that the tr…
Lab Testing, Pathology Is Fast-Growing in China
By Robert Michel | From the Volume XVIII No. 15 – November 7, 2011 Issue
CEO SUMMARY: It was record attendance at the major pathology congress which took place in Hangzhou, China, last month. Because of the ongoing growth of China’s economy, the demand for healthcare—and for high-quality clinical lab and pathology testing—is rising at an accelerated pace…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized